MedWatch

Evolva buys product from Fluxome

Creditors in the hard-tried food supplements company Fluxome have agreed to sell the company’s only marketed product to the Swiss firm Evolva.

Evolva-CEO, Neil Goldsmith | Foto: Evolva/PR

Creditors in the Danish food supplements company Fluxome, currently under reconstruction, have given the management carte blanche to negotiate a deal with Swiss outfit Evolva.

As Medwatch revealed a few weeks back, the deal concerns the right to produce the substance resveratrol, known as the health-beneficial substance found in red wine.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier